The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts - PubMed (original) (raw)

. 1994 May-Jun;14(3A):1065-70.

Affiliations

PMID: 8074451

The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts

P Goddard et al. Anticancer Res. 1994 May-Jun.

Abstract

Numerous studies performed in vitro have suggested a role for glutathione (GSH) in determining the sensitivity/resistance of tumour cells to various platinum-based drugs. Few studies have extended these findings into the in vivo setting. We have measured GSH levels in two murine (ADJ/PC6 plasmacytoma and L1210 leukaemia and their acquired platinum-drug-resistant sublines) and five human ovarian carcinoma (PXN/100, PXN/109T/C, SKOV3, HX/62 and OVCAR-3) tumour models of varying sensitivity to cisplatin. Results showed that relatively high GSH levels may be involved, at least partially, in determining platinum drug resistance in vivo in at least some of the tumour models studied (ADJ/PC6 carboplatin and tetraplatin resistant tumours; L1210 cisplatin and tetraplatin resistant tumours and the HX/62 and OVCAR-3 human ovarian carcinoma xenografts). However, in other tumours (e.g., the acquired cisplatin resistant ADJ/PC6 plasmacytoma) non-GSH mediated mechanisms of resistance (such as enhanced DNA repair) probably account for the resistance. Pretreatment of animals with oral buthionine sulfoximine (BSO), which resulted in approximately 70% depletion in tumour GSH levels, failed to potentiate the antitumour efficacy of either cisplatin (using the ADJ/PC6 and L1210 models) or the 1,2-diaminocyclohexane (DACH) platinum-drug, tetraplatin (using the ADJ/PC6 model). These BSO plus or minus cisplatin data suggest a limited role for such combinations in the clinic.

PubMed Disclaimer

Cited by

Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin Pt(IV) Derivative Having a TSPO Ligand in the Axial Position.
Savino S, Denora N, Iacobazzi RM, Porcelli L, Azzariti A, Natile G, Margiotta N. Savino S, et al. Int J Mol Sci. 2016 Jun 25;17(7):1010. doi: 10.3390/ijms17071010. Int J Mol Sci. 2016. PMID: 27347942 Free PMC article.
Nanoparticle-Mediated Delivery of Satraplatin to Overcome Cisplatin Drug Resistance.
Jiang X, Yang Q, Qi R, Yan L. Jiang X, et al. J Funct Biomater. 2023 Jul 22;14(7):387. doi: 10.3390/jfb14070387. J Funct Biomater. 2023. PMID: 37504882 Free PMC article.
Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo.
Hanigan MH, Gallagher BC, Townsend DM, Gabarra V. Hanigan MH, et al. Carcinogenesis. 1999 Apr;20(4):553-9. doi: 10.1093/carcin/20.4.553. Carcinogenesis. 1999. PMID: 10223181 Free PMC article.
Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
Tang CH, Parham C, Shocron E, McMahon G, Patel N. Tang CH, et al. Cancer Chemother Pharmacol. 2011 Jun;67(6):1389-400. doi: 10.1007/s00280-010-1435-5. Epub 2010 Aug 31. Cancer Chemother Pharmacol. 2011. PMID: 20809122 Free PMC article.

The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts - PubMed (original) (raw)